Albuvirtide

Drug Profile

Albuvirtide

Latest Information Update: 07 Jun 2016

Price : $50

At a glance

  • Originator Frontier Biotechnologies
  • Class Antivirals; Maleimides; Peptides
  • Mechanism of Action HIV envelope protein gp41 inhibitors; HIV fusion inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III HIV infections

Most Recent Events

  • 06 Jun 2016 Interim efficacy and safety data from the phase III TALENT trial in HIV infections released by Frontiers Biotechnologies
  • 06 Jun 2016 Frontier Biotechnologies announces intention to submit NDA to China Food and Drug Administration in 2016
  • 21 Mar 2016 Albuvirtide is still in phase III trials for HIV infections (Combination therapy; Treatment-experienced patients) in China (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top